Showing results (121-130 of 344) with videos related to
Sort By:
Pageof 35
Plos One|March 8, 2013
EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospitalYoon-La Choi, Jong-Mu Sun, Juhee Cho, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2019
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLCSehhoon Park, Hayoon Lee, Boram Lee, et al.Oncotarget|October 7, 2015
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancerSilvia Park, Emma Langley, Jong-Mu Sun, et al.Investigational New Drugs|May 25, 2019
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancerBo Mi Ku, Yeon Hee Bae, Kyoung Young Lee, et al.Cancer Chemotherapy and Pharmacology|July 23, 2017
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitorsHee Kyung Kim, Mi Hwa Heo, Han Sang Lee, et al.Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteriaHae Su Kim, Ji Yun Lee, Sung Hee Lim, et al.Scientific Reports|February 7, 2025
Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancerJi Eun Shin, Hyun Ae Jung, Sehhoon Park, et al.Journal of Thoracic Disease|January 10, 2017
The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutationsYoon Ki Cha, Ho Yun Lee, Myung-Ju Ahn, et al.Lung Cancer (Amsterdam, Netherlands)|December 16, 2014
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in KoreaJin Ho Baek, Jong-Mu Sun, Young Joo Min, et al.Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancerKangkook Lee, Youjin Kim, Hyun Ae Jung, et al.Pageof 35